[Sympathetic overactivity and the kidney].
Hypertension is present in the majority of patients with chronic renal failure and constitutes a major risk factor for the very high cardiovascular morbidity and mortality in this patient population. Furthermore hypertension is known to be a substantial progression factor in renal disease. In the past, it had been presumed that hypertension in chronic renal failure is due to enhanced sodium retention, chronic hypervolemia and increased activity of the renin-angiotensin-aldosterone-system. Recent studies now provide evidence that sympathetic overactivity plays an additional important role and also promotes progression of renal failure. The treatment goal in renal patients is to delay or even prevent progression of renal failure and to reduce the cardiovascular risk. Recent studies have investigated the respective impact of sympatholytic drugs, e.g. inhibitors of the renin-angiotensin-aldosterone-system, beta-blockers or I1-Imidazolin-receptor-agonists in fulfilling these aims. The present report will review experimental and clinical studies on the role of sympathetic overactivity in hypertension and chronic renal failure and possible new therapeutic options.
Habicht
Antje
A
Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Wien, Osterreich.
Watschinger
Bruno
B
D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D004195:Disease Models, Animal; D018450:Disease Progression; D006333:Heart Failure / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D006978:Hypertension, Renovascular / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D007668:Kidney / Q000503:physiopathology*; D007676:Kidney Failure, Chronic / Q000503:physiopathology* / Q000628:therapy; D016030:Kidney Transplantation; D009392:Nephrectomy; D010919:Placebos; D051381:Rats; D012078:Renal Artery Obstruction / Q000503:physiopathology; D012084:Renin-Angiotensin System / Q000502:physiology; D012307:Risk Factors; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D013997:Time Factors
D000959:Antihypertensive Agents; D010919:Placebos